Boston Scientific Taxus
This article was originally published in The Gray Sheet
Executive Summary
First PMA module for paclitaxel-eluting coronary stent is submitted to FDA. The fifth and final module will be submitted in June and include TAXUS IV clinical trial data. The results will be presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. in September (1"The Gray Sheet" Feb. 3, 2003, p. 4)...
You may also be interested in...
Dissecting DELIVER: Dosing, Non-Polymer Binding Implicated In Guidant Trial
The role of insufficient dosing in the DELIVER trial evaluating Guidant's Achieve drug-eluting stent will likely emerge in presentations at the American College of Cardiology's annual meeting in Chicago March 30-April 2
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.